Home › Corporate Profile
Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. The company's initial lead product, the TAXUS® drug-eluting coronary stent - which was co-developed and is now sold by Boston Scientific Corporation - is implanted in over five million patients worldwide.
We develop our products using a proprietary and systematic discovery approach. We use our drug screening capabilities to identify new uses for known pharmaceutical compounds. We look for compounds that address the underlying biological causes of conditions that can occur concurrently with medical device implantation, surgery or acute trauma. Once appropriate drugs have been identified, we formulate the drug, or combination of drugs, with our portfolio of biomaterials and drug delivery technologies to develop a novel drug-eluting medical device or surgical implant.
Following the acquisition of American Medical Instruments Holdings, Inc. in 2006, Angiotech expanded beyond its strong R&D capabilities to encompass the manufacturing and marketing of a wide range of single use, specialty medical devices, focused on interventional, surgical and OEM markets. Angiotech is currently working to develop a portfolio of next-generation products including its innovative Quill™ Knotless Tissue-Closure Device, which is a bidirectional, barbed wound closure device. Today, Angiotech has several specialized direct sales and distribution organizations in the United States and the European Union, as well as significant manufacturing capabilities.
At Angiotech, we are redefining success by striving to create novel medical solutions that elevate the standard of care and improve people's lives.
© Copyright 2011 Angiotech. All Rights Reserved.